Jim Cramer Endorses Medline as Best IPO of the Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: CNBC
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDLN
Wall Street analysts forecast MDLN stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 41.730
Low
42.00
Averages
47.92
High
52.00
Current: 41.730
Low
42.00
Averages
47.92
High
52.00
About MDLN
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HBSS Launches Investigation into Medline's Quality Control
- Investigation Launched: Hagens Berman Sobol Shapiro (HBSS) has initiated an investigation into Medline Inc. to determine if the company misled investors regarding its manufacturing quality controls and compliance with FDA safety standards, potentially leading to investor losses.
- Quality Control Issues: The FDA issued a warning letter to Medline on May 28, 2026, citing serious CGMP violations that rendered its drug products adulterated, raising questions about the effectiveness of its quality team.
- Severe Market Reaction: Following the revelation of quality issues, Medline's market capitalization plummeted by approximately $2.2 billion on June 3, 2026, reflecting strong investor dissatisfaction with the company's transparency.
- Potential Legal Consequences: HBSS is investigating whether Medline concealed serious concerns raised by the FDA, and if substantiated, the company may face legal liabilities and further regulatory scrutiny.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
Medline Under Investigation for Possible Securities Fraud
- FDA Warning Letter: On June 2, 2026, the U.S. FDA issued a warning letter to Medline, highlighting significant violations of Current Good Manufacturing Practice regulations, particularly the failure to thoroughly investigate unexplained discrepancies in batch specifications, which could lead to increased legal liabilities.
- Stock Price Decline: Following the FDA warning, Medline's stock price fell by $2.56, or 7.16%, closing at $33.19 per share on June 2, 2026, indicating market concerns regarding the company's compliance and management capabilities.
- Investor Litigation: Pomerantz LLP is investigating claims on behalf of Medline investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, potentially increasing the risk of class action lawsuits.
- Legal Firm Background: Pomerantz LLP is recognized as a leading firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years; adverse findings in the investigation could result in substantial damages and reputational harm for Medline.
See More
Medline Warehouse Fire Disrupts Operations
- Warehouse Fire Incident: A massive fire broke out at Medline's distribution center in Tracy, California, shortly before 1 p.m. on Friday, destroying a 1 million-square-foot facility despite aggressive firefighting efforts, due to water supply issues and high winds, which severely disrupts operational capabilities.
- Employee Safety Confirmed: Medline confirmed that all employees and on-site personnel are safe, and although the adjacent FedEx warehouse also caught fire, there were no reported injuries, demonstrating the company's effective crisis management during emergencies.
- Short-term Operational Disruption: Analysts noted that the incident will lead to the distribution facility being offline at least temporarily, prompting Medline to evaluate contingency plans to maintain customer order fulfillment, which could result in short-term disruptions in product availability and fill rates.
- Expected Financial Impact: While Medline likely has redundancy plans to mitigate short-term disruptions, analysts expect the fire to have a short-term financial impact, potentially affecting the company's market performance in the near term.
See More
Schall Law Firm Investigates Medline for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Medline Inc. regarding potential violations of securities laws, particularly focusing on whether the company issued false or misleading statements that could harm investors' interests.
- FDA Warning: According to a report by Reuters, Medline has received another warning from the U.S. FDA within two months, indicating that the company failed to thoroughly investigate microbial contamination incidents in finished drug products, highlighting serious deficiencies in quality control.
- Inadequate Cleaning Standards: The FDA's letter noted that Medline's cleaning practices were insufficient, which not only raises concerns about product quality but could also have long-term repercussions on the company's reputation and market trust.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to participate in the investigation and offers free legal consultations, demonstrating its commitment to protecting investors' rights.
See More
Symbotic Signs Healthcare Contract Amid Stock Pressure
- Customer Contract Expansion: Symbotic signed a contract with Medline, a leader in medical surgical products, in April 2026, marking a successful expansion from retail to healthcare, which is expected to provide new revenue streams and enhance market competitiveness.
- Financial Performance Improvement: In Q2, Symbotic's revenue rose 23% year-over-year to a net income of $9 million, a significant turnaround from a $10 million loss in the previous year, although the earnings of one cent per share fell short of market expectations.
- Significant Backlog: Symbotic's backlog stands at $22.7 billion, ten times its fiscal 2025 revenue, indicating that the company has effectively locked in substantial revenue for the coming years, reflecting its strong position in the rapidly growing warehouse automation market.
- Shareholder Sell-off Impact: Despite SoftBank Group and its affiliates selling 5.59 million shares of Symbotic on May 27, causing a 21.4% drop in stock price, they still hold a 31.3% stake, indicating long-term confidence in the company, which investors should monitor for market sentiment shifts.
See More
HBSS Launches Investigation into Medline's Quality Control
- Investigation Launched: Hagens Berman Sobol Shapiro (HBSS) has initiated an investigation into Medline Inc. to determine if the company misled investors regarding its manufacturing quality controls and compliance with FDA safety standards, potentially leading to investor losses.
- Quality Control Issues: The FDA issued a warning letter to Medline on May 28, 2026, citing serious CGMP violations that rendered its drug products adulterated, raising questions about the effectiveness of its quality team.
- Severe Market Reaction: Following the revelation of quality issues, Medline's market capitalization plummeted by approximately $2.2 billion on June 3, 2026, reflecting strong investor dissatisfaction with the company's transparency.
- Potential Legal Consequences: HBSS is investigating whether Medline concealed serious concerns raised by the FDA, and if substantiated, the company may face legal liabilities and further regulatory scrutiny.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
Medline Under Investigation for Possible Securities Fraud
- FDA Warning Letter: On June 2, 2026, the U.S. FDA issued a warning letter to Medline, highlighting significant violations of Current Good Manufacturing Practice regulations, particularly the failure to thoroughly investigate unexplained discrepancies in batch specifications, which could lead to increased legal liabilities.
- Stock Price Decline: Following the FDA warning, Medline's stock price fell by $2.56, or 7.16%, closing at $33.19 per share on June 2, 2026, indicating market concerns regarding the company's compliance and management capabilities.
- Investor Litigation: Pomerantz LLP is investigating claims on behalf of Medline investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, potentially increasing the risk of class action lawsuits.
- Legal Firm Background: Pomerantz LLP is recognized as a leading firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years; adverse findings in the investigation could result in substantial damages and reputational harm for Medline.
See More
Medline Warehouse Fire Disrupts Operations
- Warehouse Fire Incident: A massive fire broke out at Medline's distribution center in Tracy, California, shortly before 1 p.m. on Friday, destroying a 1 million-square-foot facility despite aggressive firefighting efforts, due to water supply issues and high winds, which severely disrupts operational capabilities.
- Employee Safety Confirmed: Medline confirmed that all employees and on-site personnel are safe, and although the adjacent FedEx warehouse also caught fire, there were no reported injuries, demonstrating the company's effective crisis management during emergencies.
- Short-term Operational Disruption: Analysts noted that the incident will lead to the distribution facility being offline at least temporarily, prompting Medline to evaluate contingency plans to maintain customer order fulfillment, which could result in short-term disruptions in product availability and fill rates.
- Expected Financial Impact: While Medline likely has redundancy plans to mitigate short-term disruptions, analysts expect the fire to have a short-term financial impact, potentially affecting the company's market performance in the near term.
See More
Schall Law Firm Investigates Medline for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Medline Inc. regarding potential violations of securities laws, particularly focusing on whether the company issued false or misleading statements that could harm investors' interests.
- FDA Warning: According to a report by Reuters, Medline has received another warning from the U.S. FDA within two months, indicating that the company failed to thoroughly investigate microbial contamination incidents in finished drug products, highlighting serious deficiencies in quality control.
- Inadequate Cleaning Standards: The FDA's letter noted that Medline's cleaning practices were insufficient, which not only raises concerns about product quality but could also have long-term repercussions on the company's reputation and market trust.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to participate in the investigation and offers free legal consultations, demonstrating its commitment to protecting investors' rights.
See More
Symbotic Signs Healthcare Contract Amid Stock Pressure
- Customer Contract Expansion: Symbotic signed a contract with Medline, a leader in medical surgical products, in April 2026, marking a successful expansion from retail to healthcare, which is expected to provide new revenue streams and enhance market competitiveness.
- Financial Performance Improvement: In Q2, Symbotic's revenue rose 23% year-over-year to a net income of $9 million, a significant turnaround from a $10 million loss in the previous year, although the earnings of one cent per share fell short of market expectations.
- Significant Backlog: Symbotic's backlog stands at $22.7 billion, ten times its fiscal 2025 revenue, indicating that the company has effectively locked in substantial revenue for the coming years, reflecting its strong position in the rapidly growing warehouse automation market.
- Shareholder Sell-off Impact: Despite SoftBank Group and its affiliates selling 5.59 million shares of Symbotic on May 27, causing a 21.4% drop in stock price, they still hold a 31.3% stake, indicating long-term confidence in the company, which investors should monitor for market sentiment shifts.
See More
